AT 00
Alternative Names: AT-00Latest Information Update: 04 Dec 2024
Price :
$50 *
At a glance
- Originator Axcynsis Therapeutics
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 22 Oct 2024 Preclinical trials in Cancer in Singapore (Parenteral), prior to October 2024 (Axcynsis Therapeutics pipeline, October 2024)
- 22 Oct 2024 Axcynsis Therapeutics announces intention to file an IND application for AT 00 in 2026 (Axcynsis Therapeutics pipeline, October 2024)